Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study

Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study

Abstract Background The phase 3 PREEMPT clinical trials confirmed the efficacy and safety of 155 U – 195 U onabotulinumtoxinA for individuals with chronic migraine (CM) and is the licensed dose in Canada and Europe. This analysis aimed to analyze the efficacy and safety parameters of 155 U – 195 U o...

Full description

Saved in:
Bibliographic Details
Main Authors: Fayyaz Ahmed, Charly Gaul, Katja Kollewe, Ritu C. Singh, Katherine Sommer
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Neurology
Subjects:
Chronic migraine
Efficacy
OnabotulinumtoxinA
Patient-reported outcomes
Safety
Real-world study
Online Access:https://doi.org/10.1186/s12883-025-04087-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12883-025-04087-7

Similar Items